Aradigm Partners With City of Hope on Cell Therapy

The collaboration aims to reduce financial and logistical barriers to specialized cell and gene therapies for eligible cancer patients.

Updated on Nov. 18, 2026 in Cancer

Isometric editorial illustration of an insulated cryogenic transport canister on a pale field with a dotted route line, in teal, cream and slate.
Aradigm and City of Hope announced a collaboration to cut financial and travel barriers that keep eligible cancer patients from cell and gene therapies. AI Illustration. Upload story photo >

Aradigm announced a strategic collaboration with City of Hope, one of the largest cancer research and treatment organizations in the country, naming City of Hope a preferred national destination for cell and gene therapy. The partnership launched a program offering members waived copays and coverage for travel and lodging.

Why it matters

Cell and gene therapies are costly, unpredictable in price, and delivered through specialized centers, which can keep eligible patients from accessing them. The collaboration seeks to coordinate employers, health plans, providers and manufacturers to address those barriers across the United States.

The figures are organization-reported capacity measures: City of Hope has performed more than 20,000 bone marrow transplants and conducts CAR T research across 13 solid tumor types and hematologic cancers at sites in California, Arizona, Illinois and Georgia. Enrollment, cost and outcome data for the new program have not yet been reported.

The players

City of Hope

City of Hope is one of the largest cancer research and treatment organizations in the United States, with care sites in California, Arizona, Illinois and Georgia.

Aradigm

Aradigm is a public benefit corporation co-founded by William Shrank, M.D., and backed by Frist Cressey, Morgan Health and Andreessen Horowitz.

The details

Under the program, members receive waived copays and coverage for travel and lodging, and Aradigm streamlines utilization management, contracting and payment models for treatment centers. The companies plan to work with employers, health plans and manufacturers to coordinate cell and gene therapy care for patients nationwide.

Timeline

  1. November 18, 2026: Aradigm announces the City of Hope collaboration.

Big Picture

The partnership builds on City of Hope's CAR T research, which dates to the late 1990s, by shifting attention from scientific development to whether eligible patients can reach these therapies. It positions access and coordination as the next challenge for cell and gene treatments.

Eligible patients who face high copays or travel costs for specialized cell and gene therapy could see those barriers reduced under the program. Those interested should review the program details directly with their care team, since eligibility and enrollment terms are not described in the source extraction.

The takeaway

Access to advanced cancer treatments depends as much on cost and logistics as on scientific progress. Patients considering cell or gene therapy can ask their care teams about financial support and travel assistance early in planning.

Further reading

Explore more on Cancer treatment advances and access.

More information

Learn about the Aradigm cell and gene therapy benefit program directly from the company.

Source note: This article includes information reported by The Manila times.